Inaktiver Wert

Andere Sprachen Cerulean Pharma Inc Nasdaq

Aktien

US15708Q1058

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

Earnings Flash (DARE) DARE BIOSCIENCE Posts Q1 Revenue $9,302	14.05.
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update	14.05.
Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024	07.05.
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network	02.05.
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts	30.04.
Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC	30.04.
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	30.04.
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	23.04.
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	23.04.
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive	11.04.
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update	28.03.
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024	21.03.
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting	22.02.
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	31.01.
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	31.01.
Daré Bioscience, Inc. Announces Executive Changes	26.01.
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer	26.01.
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned	26.01.
Daré Bioscience Announces Executive Team and Board of Directors Changes	26.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cerulean Pharma Inc Nasdaq

Aktien

US15708Q1058

Andere Sprachen

Filter